CART-ddBCMA is a cell therapy candidate involving patient-derived, or autologous, T cells that have been genetically modified to recognize and kill specific cells expressing BCMA, a target antigen for multiple myeloma. This candidate utilizes a chimeric transmembrane protein for antigen recognition that includes a novel proprietary binding domain in place of the traditional scFv binding domain of conventional cell therapies. The domain has been engineered to reduce immunogenicity. Arcellx’s CART-ddBCMA Phase 1 trial for the treatment of relapsed and refractory multiple myeloma has been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration.
ACLX-001 is in development for the treatment of multiple myeloma. ACLX-001 is composed of ARC-T cells and a bivalent SparX protein targeting BCMA. This SparX-BCMA protein utilizes the same antigen binding domain as the Arcellx CART-ddBCMA.
Arcellx is exploring additional targets for the treatment of MM.
Arcellx is developing ARC-SparX platform candidates in a range of disease areas. The pipeline is designed for efficient, stepwise development of the ARC-SparX platform.